Skip to content
Home/Companies/Biotech/Arvelle

Arvelle

Biotech·Switzerland·Exited 2021·Held 2yr
Entry
2019
Hold
2yr
Exit
2021

Who owns Arvelle?

Arvelle is a Swiss Biotech company, now owned by Angelini Pharma, which acquired it in 2021 from Andera Partners.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
Andera Partners
Investor
Andera Partners
BioDiscovery 5 · 2017 · VC

Key facts

HQSwitzerland
SectorBiotech
Exit Type
Trade Sale
Buyer
Angelini Pharma
Exit Year
2021

More from BioDiscovery 5

Other portfolio companies in the same fund.

Amolyt Pharma
Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to AstraZeneca
Evommune
Evommune
Exited 2025
BiotechFrance· 2021
to Public market (NYSE IPO ticker EVMN)
Nyxoah
Nyxoah
Active
MedTechBelgium· 2020
AgoMab
AgoMab
Exited 2026
BiotechFrance· 2019
to Public market (Nasdaq IPO ticker AGMB)
AM Pharma
AM Pharma
Active
BiotechNetherlands· 2019
Exciva
Active
BiotechUS· 2019

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Arvelle?

Arvelle is now owned by Angelini Pharma, which acquired it in 2021 from Andera Partners.

When did Angelini Pharma acquire Arvelle?

Angelini Pharma acquired Arvelle in 2021, buying from Andera Partners.

Who did Arvelle sell to?

Andera Partners sold Arvelle to Angelini Pharma in 2021 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue